Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we will assume that you are happy to receive all cookies and you will not see this message again. Click 'Find out more' for information on how to change your cookie settings.

After over ten years’ of DARPA-funded research, and in collaboration with the NIH, Professor Kieran Clarke has exclusively licensed her novel ketone monoester, ΔG®, to Silicon Valley start-up company HVMN Inc. ΔG® will be used in the world’s first ketone drink for athletes (http://hvmn.com/ketone), for use in training, endurance performance and recovery after exercise.

Papers recently published in Cell Metabolism, FASEB, Frontiers in Physiology and Obesity have caused mounting anticipation of a commercially available product. Since the launch on Monday 6 November 2017, press coverage has been high on both sides of the Atlantic, with articles in The Times, The Independent, Business Insider and Men’s Health (amongst many others).

Professor Clarke continues to collaborate with the NIH and other institutions worldwide on potential applications of ΔG®, including for obesity, metabolic disease, type 2 diabetes and neurodegenerative diseases, such as Alzheimer’s and Parkinson’s. 

bottle.jpg